P04.11
Newborn affected by maternal antineoplastic chemotherapy
Clinical Classification Guidelines
Medical Intelligence & Overview
The ICD-10 code P04.11 refers to newborns who have been affected by maternal antineoplastic chemotherapy during pregnancy. This condition arises when a pregnant woman receives chemotherapy drugs to treat cancer, which can potentially impact the developing fetus. While chemotherapy can be a life-saving treatment for the mother, it may pose risks to the unborn child. This diagnosis highlights the importance of careful medical planning and monitoring during pregnancy when cancer treatment is necessary.
Causes & Symptoms
Clinical Causes: Maternal use of antineoplastic (cancer-fighting) drugs during pregnancy Timing of chemotherapy administration, especially during the first trimester Types and dosages of chemotherapy agents used Maternal health and the severity of cancer Potential transfer of chemotherapy agents across the placenta
Key Symptoms: Low birth weight Premature birth or delivery before full term Birth defects, particularly affecting the nervous system, heart, or limbs Laboratory abnormalities such as anemia or low blood cell counts Signs of prematurity such as underdeveloped lungs or feeding difficulties Potential neurological issues, including developmental delays
Diagnostic & Treatment
Diagnosis Path: Diagnosis of a newborn affected by maternal antineoplastic chemotherapy is generally based on maternal medical history, particularly if chemotherapy was administered during pregnancy. Newborns are thoroughly examined after birth for physical anomalies and signs of developmental issues. Additional tests may include:
Treatment Protocols: Management of infants affected by maternal chemotherapy involves supportive care tailored to the child's needs. This might include:
Clinical Advice & FAQs
Billing Guidance
Is P04.11 a billable ICD-10 code?
Yes, P04.11 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report P04.11?
Clinical documentation must specify the nature of Newborn affected by maternal antineoplastic chemotherapy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference